Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06240728 · ClinicalTrials.gov registry record · Phase 1

A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

A Phase 1 study of Metastatic Malignant Neoplasm, sponsored by NextPoint Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
144
Enrollment target
8
Study locations

NCT06240728 is a Phase 1 study of Metastatic Malignant Neoplasm that is actively recruiting participants, run by NextPoint Therapeutics. The registered enrollment target is 144 participants, below the 329-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (56% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06240728, a Phase 1 study of Metastatic Malignant Neoplasm, is actively recruiting participants, sponsored by NextPoint Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
144 participants
Enrollment target
8
Study locations

Study Summary

NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treating physicians.

Conditions Studied

Metastatic Malignant Neoplasm

Interventions

  • DRUG NPX887

Study Locations (8)

Texas

  • MD Anderson Cancer Center - Houston
  • Next Oncology - San Antonio

Other

  • Severance Hospital, Yonsei University Health System - Seoul
  • Samsung Medical Center - Seoul

Maryland

  • Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center - Baltimore

Massachusetts

  • Beth Israel Deaconess Medical Center (BIDMC) - Boston

New York

  • Albert Einstein Medical College Montefiore Medical Center - The Bronx

Virginia

  • NEXT Oncology-Fairfax - Fairfax

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-01-22
Est. Completion 2027-08
Phase Phase 1

Sponsor

NextPoint Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06240728

The ClinicalTrials.gov registry entry for NCT06240728 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 15 other Metastatic Malignant Neoplasm trials with a reported enrollment target (56% lower). The listed sponsor is NextPoint Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Malignant Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which NPX887 is the first listed.

NCT06240728 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Texas, Other, Maryland.

Frequently Asked Questions

What is clinical trial NCT06240728 about?

NCT06240728 is a clinical study titled "A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2". NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (...

What is the current status of trial NCT06240728?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2024-01-22. Estimated completion is 2027-08.

What conditions does trial NCT06240728 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm.

What interventions are being tested in trial NCT06240728?

The interventions under investigation include: NPX887 (DRUG).

Who is sponsoring clinical trial NCT06240728?

This trial is sponsored by NextPoint Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06240728 being conducted?

This trial has 8 study locations across Maryland, Massachusetts, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Malignant Neoplasm

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.